Payment overview · 2025
General Payments
$1,327.61
45 reported records · 19 companies
Healthcare provider profile · identity verified
Robert A Loera, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HEMET, CA · NPI 1639287642
Verified facts
What the public records show
CMS Open Payments records show Robert A Loera, MD received $1,327.61 in general payments during 2025 across 45 reported records.
Amgen Inc. accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Nexletol, Ozempic, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TUDORZA PRESSAIR as an associated drug or biological on 89 records involving 63 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Tudorza Pressair by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $289.05 | 21.8% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $254.87 | 19.2% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $194.14 | 14.6% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $132.01 | 9.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $121.20 | 9.1% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.39 | 3.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.10 | 3.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.29 | 2.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.56 | 1.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.93 | 1.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.90 | 1.7% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.37 | 1.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.86 | 1.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.65 | 1.3% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $17.26 | 1.3% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $15.58 | 1.2% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $15.55 | 1.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.10 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.80 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,327.61 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $289.05 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $203.12 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $157.62 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $132.01 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $121.20 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $103.18 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $70.90 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.10 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.71 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| Respiratory Normalized: respiratory |
Device | Philips North America LLC | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 129 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 327 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 69 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 263 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 67 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
129 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TUDORZA PRESSAIR open payments reported associated product |
CMS Open Payments — General Payments 89 supporting records · 63 recipient NPIs · example record 1206133584 |
Tudorza Pressair · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
327 | 74 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
327 | 74 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
107 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
263 | 55 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1519 | 346 |
| Losartan Potassium | Losartan Potassium | 1122 | 275 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 666 | 122 |
| Metformin Hcl | Metformin Hcl | 638 | 153 |
| Omeprazole | Omeprazole | 624 | 153 |
| Tamsulosin Hcl | Tamsulosin Hcl | 519 | 132 |
| Gabapentin | Gabapentin | 497 | 104 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 477 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 433 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 406 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 405 | 114 |
| Pioglitazone Hcl | Pioglitazone Hcl | 396 | 93 |
| Furosemide | Furosemide | 359 | 69 |
| Meloxicam | Meloxicam | 351 | 81 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 333 | 70 |
| Jardiance | Empagliflozin | 327 | 74 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 311 | 51 |
| Glimepiride | Glimepiride | 308 | 72 |
| Ezetimibe | Ezetimibe | 304 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 290 | 68 |
| Diclofenac Sodium | Diclofenac Sodium | 287 | 63 |
| Atenolol | Atenolol | 284 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 280 | 49 |
| Tramadol Hcl | Tramadol Hcl | 279 | 72 |
| Trazodone Hcl | Trazodone Hcl | 273 | 52 |
| Lisinopril | Lisinopril | 266 | 62 |
| Ozempic | Semaglutide | 263 | 55 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 257 | 52 |
| Bupropion Xl | Bupropion Hcl | 250 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 246 | 58 |
| Alendronate Sodium | Alendronate Sodium | 224 | 68 |
| Donepezil Hcl | Donepezil Hcl | 220 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 220 | 57 |
| Pregabalin | Pregabalin | 217 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 43 |
| Topiramate | Topiramate | 190 | 36 |
| Potassium Chloride | Potassium Chloride | 188 | 44 |
| Nifedipine Er | Nifedipine | 187 | 42 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 186 | 41 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 180 | 35 |
| Finasteride | Finasteride | 172 | 47 |
| Eliquis | Apixaban | 165 | 31 |
| Lorazepam | Lorazepam | 164 | 32 |
| Ibuprofen | Ibuprofen | 157 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 155 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 41 |
| Baclofen | Baclofen | 141 | 34 |
| Buspirone Hcl | Buspirone Hcl | 141 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 137 | 20 |
| Alprazolam | Alprazolam | 136 | 22 |
| Simvastatin | Simvastatin | 136 | 32 |
| Farxiga | Dapagliflozin Propanediol | 129 | 34 |
| Sertraline Hcl | Sertraline Hcl | 125 | 37 |
| Carvedilol | Carvedilol | 122 | 38 |
| Invokana | Canagliflozin | 111 | 16 |
| Temazepam | Temazepam | 108 | 16 |
| Trulicity | Dulaglutide | 107 | 15 |
| Meclizine Hcl | Meclizine Hcl | 105 | 28 |
| Montelukast Sodium | Montelukast Sodium | 104 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | 17 |
| Xarelto | Rivaroxaban | 91 | 16 |
| Nitroglycerin | Nitroglycerin | 86 | 22 |
| Allopurinol | Allopurinol | 83 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 26 |
| Benazepril Hcl | Benazepril Hcl | 79 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 78 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 77 | 16 |
| Lidocaine | Lidocaine | 77 | 18 |
| Testosterone | Testosterone | 77 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | 13 |
| Metformin Hcl Er | Metformin Hcl | 75 | 23 |
| Clotrimazole | Clotrimazole | 73 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 71 | 14 |
| Mounjaro | Tirzepatide | 69 | 12 |
| Rybelsus | Semaglutide | 68 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 13 |
| Methocarbamol | Methocarbamol | 64 | 12 |
| Spironolactone | Spironolactone | 63 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 50 |
| Mirtazapine | Mirtazapine | 60 | 13 |
| Prednisone | Prednisone | 58 | 21 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 55 | suppressed |
| Carisoprodol | Carisoprodol | 55 | suppressed |
| Myrbetriq | Mirabegron | 55 | 11 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 13 |
| Januvia | Sitagliptin Phosphate | 54 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 14 |
| Lactulose | Lactulose | 52 | 12 |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | suppressed |
| Glipizide | Glipizide | 47 | 15 |
| Hydrocortisone | Hydrocortisone | 47 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 11 |
| Famotidine | Famotidine | 45 | 13 |
| Meloxicam | Meloxicam, Submicronized | 45 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 31 |
| Ibu | Ibuprofen | 42 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 42 | suppressed |
| Alogliptin | Alogliptin Benzoate | 41 | suppressed |
| Loperamide | Loperamide Hcl | 41 | suppressed |
| Irbesartan | Irbesartan | 40 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 39 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 39 | suppressed |
| Nystatin | Nystatin | 38 | suppressed |
| Topiramate Er | Topiramate | 37 | suppressed |
| Naproxen | Naproxen | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 26 |
| Enulose | Lactulose | 33 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Colchicine | Colchicine | 32 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Nexletol | Bempedoic Acid | 32 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 32 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 32 | 23 |
| Diazepam | Diazepam | 31 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 30 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Tudorza Pressair | Aclidinium Bromide | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 25 |
| Dapagliflozin | Dapagliflozin Propanediol | 28 | 16 |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Cycloset | Bromocriptine Mesylate | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Kerendia | Finerenone | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Permethrin | Permethrin | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 15 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Wegovy | Semaglutide | 15 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Erleada | Apalutamide | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lithobid | Lithium Carbonate | 13 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Piroxicam | Piroxicam | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Cymbalta | Duloxetine Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | 11 |
| Easy Comfort Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,327.61 · 45 records | Amgen Inc. | AIRSUPRA, AREXVY, BEXSERO, BEYFORTUS, Doc Band, FARXIGA, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, INGREZZA, JARDIANCE, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Respiratory, Symbravo, TONMYA, TRELEGY ELLIPTA, UBRELVY, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error